Can Science Make a Comeback After Theranos?
Theranos promised the next revolution in healthcare – running hundreds of lab tests with one prick of blood. The company sky-rocketed to fame, but as the public learned of the company’s deception, immediate skepticism tore through the entire biotech community. How did a young entrepreneur lead a company to a $10 billion valuation – with faulty technology?
Theranos whistleblower turned biotech founder, Tyler Shultz, will take the stage to discuss blowback from the scandal. In conversation with Kevin Hrusovsky, healthcare visionary and serial biotech entrepreneur, the two will unpack questions on advancing medicine while rebuilding trust. How does science make a comeback after Theranos? How do you ensure your customers and the public that your technology is sound and credible?
Share this idea
Additional Supporting Materials
- What can biotech companies and entrepreneurs learn from Theranos? How do we restore trust?
- How do you accelerate science with speed and transparency? Does peer review still matter?
- How do you ensure your customers and the public that your technology is sound and credible?
Stephanie Heckman, Director, Stern Strategy Group